Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

Stocks were rising Tuesday and the Nasdaq Composite turned higher for the year even as uncertainty over global trade ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to ...

In trading on Tuesday, shares of MoonLake Immunotherapeutics (Symbol: MLTX) crossed above their 200 day moving average of $45.66, changing hands as high as $49.48 per share. MoonLake ...

MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Significant improvements ...

MoonLake stock has seen a 400% increase in value since its listing on the Nasdaq, and has raised over $450 million through equity offerings. MoonLake's primary clinical asset, Sonelokimab (SLK ...